Ralph Passarella, Reify Health CEO

Reify Health thinks clin­i­cal tri­als can be rep­re­sen­ta­tive by 2030 — and it’s se­cured the cap­i­tal to help part­ners put in the work 

Drug de­vel­op­ers have lacked on the di­ver­si­ty front for years, es­pe­cial­ly when it comes to test­ing in­ves­ti­ga­tion­al treat­ments, vac­cines and oth­er tools to fight dis­eases.

The in­dus­try has beefed up re­sources and ini­tia­tives in re­cent years, but the prob­lem is like­ly to take years and years of work to en­sure clin­i­cal tri­als are rep­re­sen­ta­tive of the pop­u­la­tion and the peo­ple that are dis­pro­por­tion­ate­ly af­fect­ed by cer­tain dis­eases. And the FDA re­leased new draft guid­ance last week to tell drug­mak­ers and med­ical de­vice man­u­fac­tur­ers that they should set goals for en­roll­ment and spec­i­fy their re­ten­tion strate­gies.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.


Alexandria Real Estate Equities

Cambridge, MA, USA